XML 35 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangible Assets, Net
9 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net
Goodwill and Intangible Assets, Net
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
European Pharmaceutical Solutions
 
Medical-Surgical Solutions
 
Other
 
Total
Balance, March 31, 2019
$
4,078

 
$

 
$
2,451

 
$
2,829

 
$
9,358

Goodwill acquired

 
56

 

 

 
56

Acquisition accounting, transfers and other adjustments
1

 
4

 
7

 

 
12

Other changes/disposals
(1
)
 

 
(5
)
 

 
(6
)
Impairment charges

 

 

 
(2
)
 
(2
)
Foreign currency translation adjustments, net

 
3

 

 
35

 
38

Balance, December 31, 2019
$
4,078

 
$
63

 
$
2,453

 
$
2,862

 
$
9,456


Information regarding intangible assets is as follows:
 
December 31, 2019
 
March 31, 2019
(Dollars in millions)
Weighted
Average
Remaining
Amortization
Period
(Years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships
11
 
$
3,602

 
$
(1,792
)
 
$
1,810

 
$
3,818

 
$
(1,801
)
 
$
2,017

Service agreements
10
 
1,023

 
(479
)
 
544

 
1,017

 
(430
)
 
587

Pharmacy licenses
26
 
517

 
(229
)
 
288

 
513

 
(209
)
 
304

Trademarks and trade names
13
 
833

 
(235
)
 
598

 
887

 
(232
)
 
655

Technology
4
 
173

 
(108
)
 
65

 
141

 
(94
)
 
47

Other
5
 
278

 
(219
)
 
59

 
288

 
(209
)
 
79

Total
 
 
$
6,426


$
(3,062
)
 
$
3,364

 
$
6,664

 
$
(2,975
)
 
$
3,689


Amortization expense of intangible assets was $113 million and $343 million for the three and nine months ended December 31, 2019 and $122 million and $365 million for the three and nine months ended December 31, 2018. Estimated amortization expense of these assets is as follows: $118 million, $449 million, $357 million, $259 million and $242 million for the remainder of 2020 and each of the succeeding years through 2024 and $1.9 billion thereafter. All intangible assets were subject to amortization as of December 31, 2019 and March 31, 2019. During the nine months ended December 31, 2019 and 2018, the Company recorded impairments related to certain intangible assets in its European Pharmaceutical Solutions segment and its Rexall Health retail business within Other. Refer to Financial Note 4, “Restructuring, Impairment and Related Charges” for more information.